Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Collaboration underway to validate and discover new biomarkers for breast and ovarian cancer
November 3rd, 2005
Ciphergen Biosystems, Inc., (CIPH) announced that it has signed a research and license agreement with University College London (UCL) and UCL BioMedica, Plc., to utilize Ciphergen's suite of proteomic solutions (Deep Proteome, Pattern Track Process, and ProteinChip System) to further their ongoing research in ovarian cancer. The principal investigator, Professor Ian Jacobs of UCL and president of the European Society of Gynecological Oncology, is recognized as a world authority on ovarian cancer. He and his team manage the largest screening trial in the world - the United Kingdom Collaborative Trial of Ovarian Cancer Screening which involves 200,000 women. ...
Source: Women's Health Weekly (2005-11-03)
|
